James Brian Windsor's Insider Trades & SAST Disclosures
James Brian Windsor's most recent trade in Rein Therapeutics Inc. was a trade of 239 Common Stock done at an average price of $2.2 . Disclosure was reported to the exchange on Dec. 5, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern James Brian Windsor.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rein Therapeutics Inc. | James Brian Windsor | President and CEO | Purchase of securities on an exchange or from another person at price $ 2.24 per share. | 05 Dec 2024 | 239 | 239 (0%) | 0% | 2.2 | 535 | Common Stock |
| Rein Therapeutics Inc. | James Brian Windsor | President and CEO | Purchase of securities on an exchange or from another person at price $ 2.25 per share. | 05 Dec 2024 | 161 | 161 (0%) | 0% | 2.2 | 362 | Common Stock |
| Rein Therapeutics Inc. | James Brian Windsor | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2024 | 517,500 | 517,500 | - | - | Stock Option (right to buy) | |
| Rein Therapeutics Inc. | James Brian Windsor | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 2,000 | 7,122 (0%) | 0% | - | Common Stock | |
| Rein Therapeutics Inc. | James Brian Windsor | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 2 | 0 | - | - | Series X Non-Voting Convertible Preferred | |
| Rein Therapeutics Inc. | Brian James Windsor | President and COO | Purchase of securities on an exchange or from another person at price $ 3.37 per share. | 15 Dec 2023 | 225 | 225 (0%) | 0% | 3.4 | 758 | Common Stock |
| Tff Pharmaceuticals Inc | James Brian Windsor | Director, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. | 07 Dec 2020 | 25,000 | 30,000 (0%) | 0% | 2.5 | 62,500 | Common Stock |
| Tff Pharmaceuticals Inc | James Brian Windsor | Director, Chief Science Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2020 | 25,000 | 134,429 | - | - | Stock Options (Right to Buy) | |
| Tff Pharmaceuticals Inc | James Brian Windsor | Director, Chief Science Officer | Sale of securities on an exchange or to another person at price $ 15.80 per share. | 07 Dec 2020 | 25,000 | 5,000 (0%) | 0% | 15.8 | 395,000 | Common Stock |
| Tff Pharmaceuticals Inc | James Brian Windsor | Director, Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Aug 2020 | 20,000 | 159,429 | - | - | Stock Options (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges